- Home
- SLM vs TVTX Comparison
SLM vs TVTX Comparison
Compare SLM & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLM | TVTX |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | 1788 | 497 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | SLM | TVTX |
|---|---|---|
| Price | $22.11 | $44.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $31.09 | ★ $40.62 |
| AVG Volume (30 Days) | ★ 2.8M | 2.0M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.35 | $44.76 |
| Revenue Next Year | $5.68 | $35.51 |
| P/E Ratio | $6.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.77 | $13.88 |
| 52 Week High | $34.55 | $48.61 |
Technical Indicators
Market Signals| Indicator | SLM | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 61.88 |
| Support Level | $20.88 | $41.55 |
| Resistance Level | $22.86 | $48.61 |
| Average True Range (ATR) | 0.60 | 2.22 |
| MACD | -0.06 | -0.34 |
| Stochastic Oscillator | 57.92 | 43.35 |
Price Performance
Historical ComparisonAbout SLM SLM Corporation
SLM Corp is an education solutions company. Its business is to originate and service loans to students and their families to finance the cost of their education. The term' Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.